Your browser is no longer supported. Please, upgrade your browser.
Settings
KPTI Karyopharm Therapeutics Inc. daily Stock Chart
KPTI [NASD]
Karyopharm Therapeutics Inc.
Index- P/E- EPS (ttm)-2.97 Insider Own2.00% Shs Outstand61.80M Perf Week-6.02%
Market Cap636.54M Forward P/E- EPS next Y-3.17 Insider Trans-49.34% Shs Float48.72M Perf Month-10.82%
Income-159.20M PEG- EPS next Q-0.85 Inst Own83.20% Short Float13.94% Perf Quarter-47.82%
Sales31.70M P/S20.08 EPS this Y3.80% Inst Trans0.93% Short Ratio8.33 Perf Half Y-40.46%
Book/sh2.82 P/B3.65 EPS next Y-4.60% ROA-79.30% Target Price24.09 Perf Year-7.29%
Cash/sh3.35 P/C3.08 EPS next 5Y- ROE-104.50% 52W Range9.00 - 21.71 Perf YTD7.29%
Dividend- P/FCF- EPS past 5Y-37.30% ROI-100.90% 52W High-52.56% Beta3.74
Dividend %- Quick Ratio5.10 Sales past 5Y20.40% Gross Margin- 52W Low14.44% ATR0.76
Employees154 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)45.40 Volatility5.68% 7.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.10% Profit Margin- Rel Volume1.02 Prev Close10.10
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout- Avg Volume815.56K Price10.30
Recom1.70 SMA20-2.24% SMA50-13.51% SMA200-34.90% Volume833,452 Change1.98%
Dec-03-18Initiated B. Riley FBR Buy $23
Nov-09-18Upgrade Wedbush Neutral → Outperform $19
May-24-18Downgrade Wedbush Outperform → Neutral $20 → $19
Apr-02-18Resumed Leerink Partners Outperform $19
Nov-15-17Resumed H.C. Wainwright Buy $23
Sep-15-17Initiated RBC Capital Mkts Outperform $14
Sep-08-16Reiterated H.C. Wainwright Buy $15 → $16
Aug-30-16Upgrade Jefferies Hold → Buy
Aug-18-16Initiated H.C. Wainwright Buy $15
Jun-28-16Initiated Robert W. Baird Outperform $16
May-27-16Initiated Raymond James Outperform $13
Mar-16-16Reiterated Wedbush Outperform $38 → $16
Jan-06-16Downgrade Jefferies Buy → Hold
Dec-22-15Initiated Canaccord Genuity Buy $20
Sep-09-15Initiated Jefferies Buy
Sep-02-15Initiated JP Morgan Overweight
Aug-12-15Reiterated MLV & Co Buy $54 → $42
Jul-17-15Initiated BofA/Merrill Neutral $32
Nov-10-14Upgrade Oppenheimer Perform → Outperform $53
Nov-05-14Initiated MLV & Co Buy $54
Dec-04-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-03-18 11:00AM  Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting GlobeNewswire +5.38%
09:15AM  The 4 Healthcare Stocks To Watch On Monday ACCESSWIRE
Dec-01-18 12:00PM  Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting GlobeNewswire
Nov-13-18 08:10AM  Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-08-18 05:37PM  Edited Transcript of KPTI earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
08:35AM  Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:34AM  Karyopharm Therapeutics: 3Q Earnings Snapshot Associated Press
07:00AM  Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress GlobeNewswire
Nov-07-18 08:00AM  Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma GlobeNewswire +6.24%
07:00AM  Karyopharm to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-05-18 07:00AM  Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th GlobeNewswire
Nov-02-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-01-18 10:17AM  Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting GlobeNewswire +6.45%
07:00AM  Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018 GlobeNewswire
Oct-31-18 02:44PM  Is Karyopharm Therapeutics Inc (NASDAQ:KPTI) Potentially Underrated? Simply Wall St.
Oct-29-18 07:00AM  Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers Option GlobeNewswire
Oct-26-18 07:00AM  Karyopharm Therapeutics Announces Management Change GlobeNewswire
Oct-11-18 07:00AM  Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes GlobeNewswire
Oct-09-18 04:01PM  Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes GlobeNewswire
Oct-05-18 05:43PM  U.S. Food and Drug Administration Accepts Karyopharms New Drug Application for Selinexor and Grants Priority Review GlobeNewswire
Oct-01-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-25-18 07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-20-18 04:05PM  Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
Sep-14-18 08:38AM  The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut Benzinga
Sep-13-18 07:20PM  Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting GlobeNewswire
Sep-04-18 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:00AM  Karyopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors GlobeNewswire
Aug-29-18 07:54AM  The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent Benzinga +9.32%
07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-24-18 05:16PM  Karyopharm Therapeutics Ramps Up Hiring Ahead of Potential FDA Approval The Wall Street Journal
Aug-17-18 07:45AM  Report: Developing Opportunities within FORTERRA INC, Baytex Energy, MAG Silver, Bojangles', Ciner Resources LP, and Karyopharm Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-07-18 01:27PM  [$$] Papa John's and 3 Other Small-Cap Value Plays Barrons.com
08:35AM  Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM  Karyopharm Therapeutics: 2Q Earnings Snapshot Associated Press
07:00AM  Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress GlobeNewswire
06:30AM  Karyopharm Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 04:05PM  Karyopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma GlobeNewswire
Aug-03-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-02-18 07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
Jul-25-18 04:05PM  Karyopharm Appoints Ian Karp as Vice President, Investor and Public Relations GlobeNewswire
Jul-19-18 09:21AM  Karyopharm Initiates NDA Submission Process for Selinexor Zacks
Jul-18-18 07:00AM  Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma GlobeNewswire
Jul-11-18 07:45AM  Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks ACCESSWIRE
Jul-02-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +6.24%
Jun-25-18 07:00AM  Karyopharm Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-15-18 07:00AM  Karyopharm Presents Updated Selinexor Phase 1b/2 STOMP Myeloma Data from Multiple Combinations at the European Hematology Association 2018 Annual Meeting GlobeNewswire
Jun-13-18 07:02PM  Cramer's lightning round: I was wrong to sell Magellan Mi... CNBC Videos
06:57PM  Cramer's lightning round: I was wrong to sell Magellan Midstream Partners CNBC
Jun-01-18 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:40AM  Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks ACCESSWIRE
07:00AM  Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting GlobeNewswire
May-31-18 07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
May-30-18 07:40AM  Report: Exploring Fundamental Drivers Behind PDC Energy, Black Stone Minerals, BJ's Restaurants, Karyopharm Therapeutics, SBA Communications, and BLACKLINE INC New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
May-29-18 07:50AM  Blog Exposure - Karyopharm Inked Deal with Antengene for Development and Commercialization of Selinexor, Eltanexor, Verdinexor, and KPT-9274 in Asia ACCESSWIRE
May-24-18 07:00AM  Karyopharm and Antengene Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia GlobeNewswire -9.02%
May-17-18 10:12AM  Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting GlobeNewswire
May-16-18 05:31PM  Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting GlobeNewswire
May-15-18 09:52AM  Edited Transcript of KPTI earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-10-18 07:59AM  Karyopharm Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress GlobeNewswire
May-07-18 04:05PM  Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters Option to Purchase Additional Shares GlobeNewswire +5.28%
May-04-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.51%
May-03-18 07:00AM  Karyopharm to Report First Quarter 2018 Financial Results on May 10, 2018 GlobeNewswire
May-02-18 09:46PM  Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +6.96%
May-01-18 04:33PM  Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +10.93%
12:52PM  Why Karyopharm Therapeutics Inc. Shares Are Soaring 15% Today Motley Fool
09:52AM  Biotechnology Movers: Karyopharm Therapeutics Inc. and Regeneron Pharmaceuticals Market Exclusive
08:30AM  Today's Research Reports on Trending Tickers: Karyopharm Therapeutics and Nutrisystem ACCESSWIRE
08:24AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:51AM  Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings Benzinga
Apr-30-18 07:14PM  Newtons Karyopharm to seek FDA approval for cancer drug after trial win American City Business Journals -13.66%
04:05PM  Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma GlobeNewswire
Apr-26-18 08:39AM  Is the Options Market Predicting a Spike in Karyopharm Therapeutics (KPTI) Stock? Zacks
Apr-11-18 11:56AM  Karyopharm's Myeloma Candidate Gets Fast Track Designation Zacks
Apr-10-18 08:42AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +6.33%
07:10AM  Karyopharm Therapeutics shares surge 8% after company wins fast-track designation for cancer drug MarketWatch
07:00AM  Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma GlobeNewswire
Apr-06-18 08:43AM  Falling Earnings Estimates Signal Weakness Ahead for Karyopharm Therapeutics (KPTI) Zacks
Apr-05-18 07:45AM  Report: Developing Opportunities within Insulet, Karyopharm Therapeutics, Playa Hotels & Resorts N.V, Cision Ltd., Freightcar America, and COUPA SOFTWARE Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-02-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -6.56%
Mar-19-18 04:05PM  Karyopharm to Present Preclinical Data at the American Association for Cancer Research 2018 Annual Meeting GlobeNewswire
Mar-15-18 05:21PM  Edited Transcript of KPTI earnings conference call or presentation 15-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
07:58AM  Should Karyopharm Therapeutics Incs (NASDAQ:KPTI) Recent Earnings Decline Worry You? Simply Wall St.
07:27AM  Karyopharm Therapeutics posts 4Q loss Associated Press
07:00AM  Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress GlobeNewswire
06:30AM  Karyopharm Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-08-18 07:00AM  Karyopharm to Report Fourth Quarter and Year End 2017 Financial Results on March 15, 2018 GlobeNewswire
Mar-01-18 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-10-18 10:33AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-09-18 08:00AM  Analysis: Positioning to Benefit within AECOM, Wolverine World Wide, Dorchester Minerals, Bruker, Fred's, and Karyopharm Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-07-18 07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-01-18 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-31-18 07:00AM  Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy GlobeNewswire
Jan-26-18 08:42AM  Biotechnology Movers: Karyopharm And Synergy Market Exclusive
Jan-25-18 06:30AM  Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions GlobeNewswire +12.92%
Jan-18-18 02:32PM  Edited Transcript of KPTI earnings conference call or presentation 2-Nov-17 12:30pm GMT Thomson Reuters StreetEvents
Jan-03-18 07:00AM  Karyopharm Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-10-17 06:05PM  Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting GlobeNewswire
06:00PM  Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting GlobeNewswire
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shacham SharonPresident & CSODec 07Option Exercise0.0312,500413726,010Dec 10 04:28 PM
Kauffman MichaelChief Executive OfficerDec 07Option Exercise0.0312,500413726,010Dec 10 04:29 PM
Shacham SharonPresident & CSODec 07Sale10.1112,500126,423713,510Dec 10 04:28 PM
Kauffman MichaelChief Executive OfficerDec 07Sale10.1112,500126,423713,510Dec 10 04:29 PM
Kauffman MichaelChief Executive OfficerNov 26Option Exercise4.759,60045,619521,743Nov 27 04:17 PM
Shacham SharonPresident & CSONov 26Option Exercise4.759,60045,619521,743Nov 27 04:20 PM
Kauffman MichaelChief Executive OfficerNov 26Sale11.009,600105,600512,143Nov 27 04:17 PM
Shacham SharonPresident & CSONov 26Sale11.009,600105,600512,143Nov 27 04:20 PM
Kauffman MichaelChief Executive OfficerNov 19Option Exercise4.754001,901512,543Nov 21 08:00 AM
Shacham SharonPresident & CSONov 19Option Exercise4.754001,901512,543Nov 21 08:03 AM
Kauffman MichaelChief Executive OfficerNov 19Sale11.144004,455512,143Nov 21 08:00 AM
Shacham SharonPresident & CSONov 19Sale11.144004,455512,143Nov 21 08:03 AM
Shacham SharonPresident & CSONov 07Option Exercise0.0312,500413726,010Nov 09 04:16 PM
Kauffman MichaelChief Executive OfficerNov 07Option Exercise0.0312,500413726,010Nov 09 04:17 PM
Shacham SharonPresident & CSONov 07Sale11.6512,500145,593713,510Nov 09 04:16 PM
Kauffman MichaelChief Executive OfficerNov 07Sale11.6512,500145,593713,510Nov 09 04:17 PM
Shacham SharonPresident & CSOOct 18Option Exercise4.7510,00047,520522,143Oct 22 04:09 PM
Kauffman MichaelChief Executive OfficerOct 18Option Exercise4.7510,00047,520522,143Oct 22 04:06 PM
Shacham SharonPresident & CSOOct 18Sale12.6310,000126,304512,143Oct 22 04:09 PM
Kauffman MichaelChief Executive OfficerOct 18Sale12.6310,000126,304512,143Oct 22 04:06 PM
Shacham SharonPresident & CSOOct 08Option Exercise0.0312,500413726,010Oct 09 08:00 AM
Kauffman MichaelChief Executive OfficerOct 08Option Exercise0.0312,500413726,010Oct 09 08:05 AM
Shacham SharonPresident & CSOOct 08Sale15.7512,500196,832713,510Oct 09 08:00 AM
Kauffman MichaelChief Executive OfficerOct 08Sale15.7512,500196,832713,510Oct 09 08:05 AM
Kauffman MichaelChief Executive OfficerSep 18Option Exercise4.7510,00047,520522,143Sep 18 05:23 PM
Shacham SharonPresident & CSOSep 18Option Exercise4.7510,00047,520522,143Sep 18 05:26 PM
Kauffman MichaelChief Executive OfficerSep 18Sale18.2610,000182,615512,143Sep 18 05:23 PM
Shacham SharonPresident & CSOSep 18Sale18.2610,000182,615512,143Sep 18 05:26 PM
Primiano Christopher BrettEVP, CBO, GC & SecretarySep 10Option Exercise8.4710,00084,65012,881Sep 11 06:08 PM
Primiano Christopher BrettEVP, CBO, GC & SecretarySep 10Sale18.9010,000189,0462,881Sep 11 06:08 PM
Shacham SharonPresident & CSOSep 07Option Exercise0.0312,500413726,010Sep 10 04:11 PM
Kauffman MichaelChief Executive OfficerSep 07Option Exercise0.0312,500413726,010Sep 10 04:13 PM
Shacham SharonPresident & CSOSep 07Sale19.3112,500241,384713,510Sep 10 04:11 PM
Kauffman MichaelChief Executive OfficerSep 07Sale19.3112,500241,384713,510Sep 10 04:13 PM
Chione Ltd10% OwnerSep 06Sale20.524,80098,4747,631,267Sep 07 06:27 PM
Chione Ltd10% OwnerSep 05Sale21.06160,0003,370,2567,636,067Sep 07 06:27 PM
Chione Ltd10% OwnerSep 04Sale20.6040,000824,0727,796,067Sep 04 06:59 PM
Chione Ltd10% OwnerAug 31Sale21.0511,468241,3967,836,067Sep 04 06:59 PM
Mirza Mansoor RazaDirectorAug 30Option Exercise1.922,5004,8102,236Sep 04 04:10 PM
Mirza Mansoor RazaDirectorAug 30Sale21.002,50052,5000Sep 04 04:10 PM
Chione Ltd10% OwnerAug 30Sale21.00200,0004,199,9007,847,535Sep 04 06:59 PM
Mirza Mansoor RazaDirectorAug 29Option Exercise1.492,5003,7132,500Aug 30 04:38 PM
Mirza Mansoor RazaDirectorAug 29Sale20.002,50050,0000Aug 30 04:38 PM
Chione Ltd10% OwnerAug 29Sale19.59200,0003,918,2808,047,535Aug 29 08:12 PM
Chione Ltd10% OwnerAug 27Sale18.5214,026259,7768,247,535Aug 29 08:12 PM
Kauffman MichaelChief Executive OfficerAug 20Option Exercise4.7510,00047,520522,143Aug 21 04:11 PM
Shacham SharonPresident & CSOAug 20Option Exercise4.7510,00047,520522,143Aug 21 04:14 PM
Shacham SharonPresident & CSOAug 20Sale17.4610,000174,568512,143Aug 21 04:14 PM
Kauffman MichaelChief Executive OfficerAug 20Sale17.4610,000174,568512,143Aug 21 04:11 PM
Chione Ltd10% OwnerAug 10Sale18.5070212,9878,261,561Aug 14 07:08 PM
Chione Ltd10% OwnerAug 09Sale18.5167,4741,248,7828,262,263Aug 09 08:24 PM
Chione Ltd10% OwnerAug 08Sale18.612,80052,0988,329,737Aug 09 08:24 PM
Shacham SharonPresident & CSOAug 07Option Exercise0.0312,500413726,010Aug 08 04:04 PM
Kauffman MichaelChief Executive OfficerAug 07Option Exercise0.0312,500413726,010Aug 08 04:08 PM
Shacham SharonPresident & CSOAug 07Sale18.0412,500225,556713,510Aug 08 04:04 PM
Chione Ltd10% OwnerAug 07Sale18.6010,602197,1978,332,537Aug 09 08:24 PM
Kauffman MichaelChief Executive OfficerAug 07Sale18.0412,500225,556713,510Aug 08 04:08 PM
Chione Ltd10% OwnerJul 25Sale18.5289516,5718,343,139Jul 25 07:55 PM
Chione Ltd10% OwnerJul 24Sale18.639,144170,3428,344,034Jul 25 07:55 PM
Chione Ltd10% OwnerJul 23Sale18.6620,000373,2228,353,178Jul 25 07:55 PM
Chione Ltd10% OwnerJul 20Sale19.2126,742513,8058,373,178Jul 23 05:00 PM
Chione Ltd10% OwnerJul 19Sale18.90100,0001,889,9408,399,920Jul 23 05:00 PM
Kauffman MichaelChief Executive OfficerJul 18Option Exercise2.1710,00021,678522,143Jul 20 04:23 PM
Shacham SharonPresident & CSOJul 18Option Exercise2.1710,00021,678522,143Jul 20 04:28 PM
Shacham SharonPresident & CSOJul 18Sale18.2710,000182,686512,143Jul 20 04:28 PM
Kauffman MichaelChief Executive OfficerJul 18Sale18.2710,000182,686512,143Jul 20 04:23 PM
Chione Ltd10% OwnerJul 18Sale18.5330,000556,0058,499,920Jul 18 07:34 PM
Chione Ltd10% OwnerJul 17Sale18.5017,346320,9018,529,920Jul 18 07:34 PM
Chione Ltd10% OwnerJul 16Sale18.522,65449,1618,547,266Jul 18 07:34 PM
Shacham SharonPresident & CSOJul 09Option Exercise0.0312,500413726,010Jul 10 04:09 PM
Kauffman MichaelChief Executive OfficerJul 09Option Exercise0.0312,500413726,010Jul 10 04:10 PM
Shacham SharonPresident & CSOJul 09Sale18.7212,500233,990713,510Jul 10 04:09 PM
Kauffman MichaelChief Executive OfficerJul 09Sale18.7212,500233,990713,510Jul 10 04:10 PM
Kauffman MichaelChief Executive OfficerJun 18Option Exercise0.2610,0002,640522,143Jun 19 04:05 PM
Shacham SharonPresident & CSOJun 18Option Exercise0.2610,0002,640522,143Jun 19 04:06 PM
Shacham SharonPresident & CSOJun 18Sale18.6610,000186,558512,143Jun 19 04:06 PM
Kauffman MichaelChief Executive OfficerJun 18Sale18.6610,000186,558512,143Jun 19 04:05 PM
Shacham SharonPresident & CSOJun 07Option Exercise0.2610,0002,570723,510Jun 11 04:11 PM
Kauffman MichaelChief Executive OfficerJun 07Option Exercise0.2610,0002,570723,510Jun 11 04:17 PM
Kauffman MichaelChief Executive OfficerJun 07Sale17.3010,000172,991713,510Jun 11 04:17 PM
Shacham SharonPresident & CSOJun 07Sale17.3010,000172,991713,510Jun 11 04:11 PM
Kauffman MichaelChief Executive OfficerMay 18Option Exercise0.2610,0002,640522,143May 21 04:26 PM
Shacham SharonPresident & CSOMay 18Option Exercise0.2610,0002,640522,143May 21 04:28 PM
Shacham SharonPresident & CSOMay 18Sale19.3910,000193,870512,143May 21 04:28 PM
Kauffman MichaelChief Executive OfficerMay 18Sale19.3910,000193,870512,143May 21 04:26 PM
Mirza Mansoor RazaDirectorMay 10Option Exercise1.072,0002,1461,325May 11 04:08 PM
Mirza Mansoor RazaDirectorMay 10Sale18.002,00036,0000May 11 04:08 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryMay 10Sale18.012,00036,0242,881May 10 04:10 PM
Shacham SharonPresident & CSOMay 07Option Exercise0.2610,0002,640723,510May 08 04:19 PM
Kauffman MichaelChief Executive OfficerMay 07Option Exercise0.2610,0002,640723,510May 08 04:21 PM
Kauffman MichaelChief Executive OfficerMay 07Sale16.7710,000167,747713,510May 08 04:21 PM
Shacham SharonPresident & CSOMay 07Sale16.7710,000167,747713,510May 08 04:19 PM
Kauffman MichaelChief Executive OfficerApr 18Option Exercise0.2610,0002,640522,143Apr 20 04:06 PM
Shacham SharonPresident & CSOApr 18Option Exercise0.2610,0002,640522,143Apr 20 04:07 PM
Shacham SharonPresident & CSOApr 18Sale14.7910,000147,878512,143Apr 20 04:07 PM
Kauffman MichaelChief Executive OfficerApr 18Sale14.7910,000147,878512,143Apr 20 04:06 PM
Shacham SharonPresident & CSOApr 09Option Exercise0.2610,0002,640723,510Apr 10 04:17 PM
Kauffman MichaelChief Executive OfficerApr 09Option Exercise0.2610,0002,640723,510Apr 10 04:20 PM
Kauffman MichaelChief Executive OfficerApr 09Sale12.4810,000124,829713,510Apr 10 04:20 PM
Shacham SharonPresident & CSOApr 09Sale12.4810,000124,829713,510Apr 10 04:17 PM